Jci_page_head_homepage_01 Jci_page_head_homepage_02
Matthew P. Vincenti, Constance E. Brinckerhoff
Published in Volume 108, Issue 2
J Clin Invest. 2001; 108(2):181–183 doi:10.1172/JCI13508
Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1

IL-1 activation of MAPK pathways. IL-1 binds to its cellular receptor and activates receptor-associated proteins (red), such as IRAK, TRAF6, and TAK1. The result is activation of several MAPK kinases (MKK6, MKK4, MKK7, and MEK1; green), which phosphorylate and active the MAPKs p38, JNK, and ERK (blue). SB203580 inhibits the p38 kinases, while PD98059 blocks activation of MEK1, and as a consequence ERK activation. SP600125 is a novel inhibitor of JNK, described by Han et al. in a recent issue of the JCI (13).